Global reach, higher impact
J Cancer 2011; 2:339-340. doi:10.7150/jca.2.339
Short Report
Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft
Hematology and BMT Unit, Department of Oncology, San Raffaele Scientific Institute, Milano, Italy
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Citation:
Ciceri F, Bregni M, Peccatori J. Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft. J Cancer 2011; 2:339-340. doi:10.7150/jca.2.339. Available from https://www.jcancer.org/v02p0339.htm
Ciceri F, Bregni M, Peccatori J. Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft. J Cancer 2011; 2:339-340. doi:10.7150/jca.2.339. Available from https://www.jcancer.org/v02p0339.htm
Abstract
We exploited the dual positive effects of rapamycin to prevent GvHD and control malignant cells upon infusion of unmanipulated grafts from family haploidentical donors to patients affected by advanced hematological malignancies. Preliminary results on 45 patients show the feasibility of this platform with an appreciable low rate of GvHD.
Keywords: Stem Cell Transplantation, Haploidentical, Donor Graft